Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.56 |
| ▸ | ANPEP | P15144 | 6/20 | 0.53 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8716246 | 0.83 | PRCP (0.47) | HTR2AANPEPPRCPHRH1HTR2C | |
| SCHEMBL11732915 | 0.82 | HTR2A (0.50) | HTR2AANPEPHDAC4HDAC7HDAC5 | |
| SCHEMBL15035238 | 0.78 | ACHE (0.46) | HTR2AANPEPHTR2C | |
| SCHEMBL23605201 | 0.75 | PRCP (0.55) | HTR2APRCPHRH1HTR2C | |
| SCHEMBL26815155 | 0.74 | ANPEP (0.50) | HTR2AANPEPPRCPHRH1HTR2C | |
| SCHEMBL30633009 | 0.74 | ANPEP (0.59) | HTR2AANPEPHRH1HTR2CHDAC4 | |
| SCHEMBL2187484 | 0.74 | ANPEP (0.59) | HTR2AANPEPHRH1HTR2CHDAC4 | |
| SCHEMBL24119535 | 0.73 | HTR2A (0.44) | HTR2AANPEPPRCPHRH1HTR2C | |
| SCHEMBL7385236 | 0.73 | ANPEP (0.41) | HTR2AANPEPHDAC4HDAC7HDAC5 | |
| SCHEMBL17070963 | 0.72 | ANPEP (0.57) | HTR2AANPEPHRH1HTR2CHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | HTR2A 2991/4885ANPEP 3936/4885PRCP 2942/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | HTR2A 4866/4885ANPEP 463/4885PRCP 250/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR2A 4866/4885ANPEP 463/4885PRCP 250/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | HTR2A 4866/4885ANPEP 463/4885PRCP 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.